论文部分内容阅读
Objective:The aim of this study was to evaluate the ef icacy and safety profile of DeFazio (S-1) combined with oxaliplatin against unresectable advanced or metastatic gastric cancer. Methods:Oxaliplatin was given intravenously at 130 mg/m2 for 2 h on d1 and S-1 was administered bid. at 80 mg/m2/day on d1–14 fol owed by a 7-day rest during the 3-week schedule. Results:Al 62 patients were assessed for ef icacy and adverse events. The response and disease control rates were 47.3%and 80.8%, respectively. The median time to progression was 7.8 months, and the median overal survival was 11.6 months. The grade 3/4 adverse events were hematological toxicities, including neutropenia (11.3%), thrombocytopenia (9.7%) and gastrointestinal reactions (6.5%). Conclusion:The SOX regimen (oxaliplatin, 130 mg/m2 d1;S-1, 80 mg/m2/day, bid. d1-14, q3w) provide a favorable ef icacy and safety profile in patients with advanced gastric cancer.